Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 336 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Vulnerability in Brain Tumors May Open Door to New Treatments September 26, 2022 Opinion: ‘Beating cancer means beating it for everyone’ January 29, 2021 What to Know About Treatment Options Before and After Surgery for... November 7, 2023 NHS England change of chief executive – what does it mean... August 19, 2021 Load more HOT NEWS FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves... 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail...
